1
|
Loganadan NK, Huri HZ, Vethakkan SR and
Hussein Z: Genetic markers predicting sulphonylurea treatment
outcomes in type 2 diabetes patients: Current evidence and
challenges for clinical implementation. Pharmacogenomics J.
16:209–219. 2016.PubMed/NCBI View Article : Google Scholar
|
2
|
Fowler JM: Microvascular and Macrovascular
Complications of Diabetes. Clin Diabetes. 26:77–82. 2008.
View Article : Google Scholar
|
3
|
World Health Organization (WHO): The top
10 causes of death. WHO, Geneva, 2019 https://www.who.int/es/news-room/fact-sheets/detail/the-top-10-causes-of-death
Accesed March 1. 2019.
|
4
|
Instituto Nacional de Estadística y
Geografía (INEGI): Mortalidad. Conjunto de datos: Mortalidad
General. INEGI, Aguascalientes, 2019 https://www.inegi.org.mx/sistemas/olap/consulta/general_ver4/MDXQueryDatos.asp?#Regreso&c=11144.
Accesed March 1. 2019.
|
5
|
Guariguata L, Whiting DR, Hambleton I,
Beagley J, Linnenkamp U and Shaw JE: Global estimates of diabetes
prevalence for 2013 and projections for 2035. Diabetes Res Clin
Pract. 103:137–149. 2014.PubMed/NCBI View Article : Google Scholar
|
6
|
He YY, Zhang R, Shao XY, Hu C, Wang CR, Lu
JX, Bao YQ, Jia WP and Xiang KS: Association of KCNJ11 and ABCC8
genetic polymorphisms with response to repaglinide in Chinese
diabetic patients. Acta Pharmacol Sin. 29:983–989. 2008.PubMed/NCBI View Article : Google Scholar
|
7
|
Javorsky M, Klimcakova L, Schroner Z,
Zidzik J, Babjakova E, Fabianova M, Kozarova M, Tkacova R,
Salagovic J and Tkac I: KCNJ11 gene E23K variant and therapeutic
response to sulfonylureas. Eur J Intern Med. 23:245–249.
2012.PubMed/NCBI View Article : Google Scholar
|
8
|
Zhao H, Liu S, Long M, Peng L, Deng H and
You Y: Arg972 insulin receptor substrate-1 polymorphism and risk
and severity of rheumatoid arthritis. Int J Rheum Dis. 19:141–145.
2016.PubMed/NCBI View Article : Google Scholar
|
9
|
Huri HZ, Makmor-Bakry M, Hashim R, Mustafa
N and Wan Ngah WZ: Optimisation of glycaemic control during
episodes of severe/acute hyperglycaemia in patients with type 2
diabetes mellitus. Int J Clin Pharm. 34:863–870. 2012.PubMed/NCBI View Article : Google Scholar
|
10
|
Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW,
Cha BS, Lim SK, Nam CM and Lee HC: Effects of Pro12Ala polymorphism
of peroxisome proliferator-activated receptor gamma2 gene on
rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther.
78:202–208. 2005.PubMed/NCBI View Article : Google Scholar
|
11
|
Hsieh MC, Lin KD, Tien KJ, Tu ST, Hsiao
JY, Chang SJ, Lin SR, Shing SJ and Chen HC: Common polymorphisms of
the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and
peroxisome proliferator-activated receptor-gamma coactivator-1
(Gly482Ser) and the response to pioglitazone in Chinese patients
with type 2 diabetes mellitus. Metabolism. 59:1139–1144.
2010.PubMed/NCBI View Article : Google Scholar
|
12
|
Riddle MC: Standards of Diabetes
Care-2019. Diabetes Care. 42 (Suppl 1):S80–S102. 2019. View Article : Google Scholar
|
13
|
Kalra S, Madhu SV and Bajaj S:
Sulfonylureas: Assets in the past, present and future. Indian J
Endocrinol Metab. 19:314–316. 2015.PubMed/NCBI View Article : Google Scholar
|
14
|
Modificacion a la Norma Oficial Mexicana
NOM-015-SSA2-1994 Para la prevención tratamiento y control de la
diabetes mellitus en la atención primaria para quedar como Norma
Oficial Mexicana NOM-015-SSA2-1994 Para la prevención tratamiento y
control de la diabetes. Diario Oficial de la Federación, Ciudad de
México, pp1-40. 2010.
|
15
|
Gutiérrez JP, Rivera-Dommarco J,
Shamah-Levy T, Villalpando-Hernández S, Franco A, Cuevas-Nasu L,
Romero-Martínez M and Hernández-Ávila M: Encuesta Nacional de Salud
y Nutrición 2012. Resultados Nacionales México. Instituto Nacional
de Salud Pública, Cuernavaca. 2012.
|
16
|
Hernández Avila M, Rivera Dommarco J,
Shamah Levy T, Cuevas Nasu L, Gómez Acosta L and Gaona Pineda EB:
Encuesta Nacional de Salud y Nutrición de Medio Camino 2016:
Informe final de Resultados. Instituto Nacional de Salud Pública,
Cuernavaca. pp46–54. 2016.
|
17
|
Daniels MA, Kan C, Willmes DM, Ismail K,
Pistrosch F, Hopkins D, Mingrone G, Bornstein SR and Birkenfeld AL:
Pharmacogenomics in type 2 diabetes: Oral antidiabetic drugs.
Pharmacogenomics J. 16:399–410. 2016.PubMed/NCBI View Article : Google Scholar
|
18
|
Nathan DM, Buse JB, Davidson MB,
Ferrannini E, Holman RR, Sherwin R and Zinman B: American Diabetes
Association; European Association for Study of Diabetes Medical
management of hyperglycemia in type 2 diabetes: A consensus
algorithm for the initiation and adjustment of therapy: a consensus
statement of the American Diabetes Association and the European
Association for the Study of Diabetes. Diabetes Care. 32:193–203.
2009.PubMed/NCBI View Article : Google Scholar
|
19
|
Wang B, Wang J, Huang SQ, Su HH and Zhou
SF: Genetic polymorphism of the human cytochrome P450 2C9 gene and
its clinical significance. Curr Drug Metab. 10:781–834.
2009.PubMed/NCBI View Article : Google Scholar
|
20
|
Surendiran A, Pradhan SC, Agrawal A,
Subrahmanyam DK, Rajan S, Anichavezhi D and Adithan C: Influence of
CYP2C9 gene polymorphisms on response to glibenclamide in type 2
diabetes mellitus patients. Eur J Clin Pharmacol. 67:797–801.
2011.PubMed/NCBI View Article : Google Scholar
|
21
|
Salam RFA, Zeyada R and Osman NA: Effect
of CYP2C9 gene polymorphisms on response to treatment with
sulfonylureas in a cohort of Egyptian type 2 diabetes mellitus
patients. Comp Clin Pathol. 23:341–346. 2014. View Article : Google Scholar
|
22
|
Kirchheiner J, Roots I, Goldammer M,
Rosenkranz B and Brockmöller J: Effect of genetic polymorphisms in
cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of
oral antidiabetic drugs: Clinical relevance. Clin Pharmacokinet.
44:1209–1225. 2005.PubMed/NCBI View Article : Google Scholar
|
23
|
Swen JJ, Wessels JA, Krabben A, Assendelft
WJ and Guchelaar HJ: Effect of CYP2C9 polymorphisms on prescribed
dose and time-to-stable dose of sulfonylureas in primary care
patients with Type 2 diabetes mellitus. Pharmacogenomics.
11:1517–1523. 2010.PubMed/NCBI View Article : Google Scholar
|
24
|
Bozkurt O, de Boer A, Grobbee DE, Heerdink
ER, Burger H and Klungel OH: Pharmacogenetics of glucose-lowering
drug treatment: A systematic review. Mol Diagn Ther. 11:291–302.
2007.PubMed/NCBI View Article : Google Scholar
|
25
|
Hatta FH, Teh LK, Helldén A, Hellgren KE,
Roh HK, Salleh MZ, Aklillu E and Bertilsson L: Search for the
molecular basis of ultra-rapid CYP2C9-catalysed metabolism:
Relationship between SNP IVS8-109A>T and the losartan metabolism
phenotype in Swedes. Eur J Clin Pharmacol. 68:1033–1042.
2012.PubMed/NCBI View Article : Google Scholar
|
26
|
Dorado P, Gallego A, Peñas-LLedó E, Terán
E and LLerena A: Relationship between the CYP2C9 IVS8-109A>T
polymorphism and high losartan hydroxylation in healthy Ecuadorian
volunteers. Pharmacogenomics. 15:1417–1421. 2014.PubMed/NCBI View Article : Google Scholar
|
27
|
Rubí-Castellanos R, Anaya-Palafox M,
Mena-Rojas E, Bautista-España D, Muñoz-Valle JF and
Rangel-Villalobos H: Genetic data of 15 autosomal STRs (Identifiler
kit) of three Mexican Mestizo population samples from the States of
Jalisco (West), Puebla (Center), and Yucatan (Southeast). Forensic
Sci Int Genet. 3:e71–e76. 2009.PubMed/NCBI View Article : Google Scholar
|
28
|
Dorado P, Sosa-Macias MG, Peñas-Lledó EM,
Alanis-Bañuelos RE, Wong ML, Licinio J, Lares-Asseff I and Llerena
A: CYP2C9 allele frequency differences between populations of
Mexican-Mestizo, Mexican-Tepehuano, and Spaniards. Pharmacogenomics
J. 11:108–112. 2011.PubMed/NCBI View Article : Google Scholar
|
29
|
Ortega-Vázquez A, Dorado P, Fricke-Galindo
I, Jung-Cook H, Monroy-Jaramillo N, Martínez-Juárez IE,
Familiar-López I, Peñas-Lledó E, LLerena A and López-López M:
CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma
concentrations in Mexican-Mestizo patients with epilepsy.
Pharmacogenomics J. 16:286–292. 2016.PubMed/NCBI View Article : Google Scholar
|
30
|
Reinhauer H, Home PD, Kanagasabapathy A
and Heuck CC (eds): Laboratory Diagnosis and Monitoring of Diabetes
Mellitus. World Health Organization, Madrid. pp1–59. 2003.
|
31
|
World Health Organization (WHO): Technical
Report Series. Expert Comittee on Physical Status: the Use and
Interpretation of Anthropometry Physical Status. WHO, Geneva,
pp312-344. 1995.
|
32
|
Holstein A, Plaschke A, Ptak M, Egberts
EH, El-Din J, Brockmöller J and Kirchheiner J: Association between
CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on
medication with sulphonylurea hypoglycaemic agents. Br J Clin
Pharmacol. 60:103–106. 2005.PubMed/NCBI View Article : Google Scholar
|
33
|
Holstein A, Hahn M, Patzer O, Seeringer A,
Kovacs P and Stingl J: Impact of clinical factors and CYP2C9
variants for the risk of severe sulfonylurea-induced hypoglycemia.
Eur J Clin Pharmacol. 67:471–476. 2011.PubMed/NCBI View Article : Google Scholar
|
34
|
Becker ML, Visser LE, Trienekens PH,
Hofman A, van Schaik RH and Stricker BH: Cytochrome P450 2C9 *2 and
*3 polymorphisms and the dose and effect of sulfonylurea in type II
diabetes mellitus. Clin Pharmacol Ther. 83:288–292. 2008.PubMed/NCBI View Article : Google Scholar
|
35
|
Zhou K, Donnelly L, Burch L, Tavendale R,
Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Lang CC,
et al: Loss-of-function CYP2C9 variants improve therapeutic
response to sulfonylureas in type 2 diabetes: A Go-DARTS study.
Clin Pharmacol Ther. 87:52–56. 2010.PubMed/NCBI View Article : Google Scholar
|
36
|
Klen J, Dolžan V and Janež A: CYP2C9,
KCNJ11 and ABCC8 polymorphisms and the response to sulphonylurea
treatment in type 2 diabetes patients. Eur J Clin Pharmacol.
70:421–428. 2014.PubMed/NCBI View Article : Google Scholar
|
37
|
Ragia G, Tavridou A, Elens L, Van Schaik
RH and Manolopoulos VG: CYP2C9*2 allele increases risk for
hypoglycemia in POR*1/*1 type 2 diabetic patients treated with
sulfonylureas. Exp Clin Endocrinol Diabetes. 122:60–63.
2014.PubMed/NCBI View Article : Google Scholar
|
38
|
Hohendorff J, Mrozinska S, Plis A, Nowak
N, Klupa T and Malecki MT: Lack of Association between Arg144Cys
Variant of CYP2C9 Gene and Therapeutic Response to Oral Agents in
Type 2 Diabetes Patients. Int J Hum Genet. 12:83–86. 2012.
View Article : Google Scholar
|
39
|
Bhatt D, Chauhan N, Sharma A, Dhawan D,
Bhatt RV, Phatak S and Padh H: Investigating the role of plasma
glucose concentration as a phenotypic marker for CYP2C9 genetic
variants, in the diabetic population of Gujarat. Indian J Pharm
Sci. 76:72–77. 2014.PubMed/NCBI
|
40
|
Zeng W, Guo Y, Chen P, Liu Z, Chen D and
Han C: CYP2C93 variant is associated with antidiabetes efficacy of
gliclazide in Chinese type 2 diabetes patients. J Diabetes
Investig. 7:764–768. 2016.PubMed/NCBI View Article : Google Scholar
|
41
|
Suzuki K, Yanagawa T, Shibasaki T, Kaniwa
N, Hasegawa R and Tohkin M: Effect of CYP2C9 genetic polymorphisms
on the efficacy and pharmacokinetics of glimepiride in subjects
with type 2 diabetes. Diabetes Res Clin Pract. 72:148–154.
2006.PubMed/NCBI View Article : Google Scholar
|
42
|
Gonzalez-Covarrubias V, Martínez-Magaña
JJ, Coronado-Sosa R, Villegas-Torres B, Genis-Mendoza AD,
Canales-Herrerias P, Nicolini H and Soberón X: Exploring Variation
in Known Pharmacogenetic Variants and its Association with Drug
Response in Different Mexican Populations. Pharm Res. 33:2644–2652.
2016.PubMed/NCBI View Article : Google Scholar
|
43
|
Aguilar B, Rojas JC and Collados MT:
Prevalence of CYP2C9 variants in the Mexican population. Arch Med
Res. 39(463)2008.PubMed/NCBI View Article : Google Scholar
|
44
|
Castelán-Martínez OD, Hoyo-Vadillo C,
Sandoval-García E, Sandoval-Ramírez L, González-Ibarra M,
Solano-Solano G, Gómez-Díaz RA, Parra EJ, Cruz M and
Valladares-Salgado A: Allele frequency distribution of CYP2C9 2 and
CYP2C9 3 polymorphisms in six Mexican populations. Gene.
523:167–172. 2013.PubMed/NCBI View Article : Google Scholar
|
45
|
Saldaña-Cruz AM, León-Moreno LC,
Sánchez-Corona J, Santiago DA, Mendoza-Carrera F, Castro-Martínez
XH, García-Zapién AG, Morán-Moguel MC and Flores-Martínez SE:
CYP2C9 and CYP2C19 Allele and Haplotype Distributions in Four
Mestizo Populations from Western Mexico: An Interethnic Comparative
Study. Genet Test Mol Biomarkers. 20:702–709. 2016.PubMed/NCBI View Article : Google Scholar
|
46
|
Maekawa K, Fukushima-Uesaka H, Tohkin M,
Hasegawa R, Kajio H, Kuzuya N, Yasuda K, Kawamoto M, Kamatani N,
Suzuki K, et al: Four novel defective alleles and comprehensive
haplotype analysis of CYP2C9 in Japanese. Pharmacogenet Genomics.
16:497–514. 2006.PubMed/NCBI View Article : Google Scholar
|
47
|
Lee SJ, Jang YJ, Cha EY, Kim HS, Lee SS
and Shin JG: A haplotype of CYP2C9 associated with warfarin
sensitivity in mechanical heart valve replacement patients. Br J
Clin Pharmacol. 70:213–221. 2010.PubMed/NCBI View Article : Google Scholar
|
48
|
Jimenez-Sanchez G: Developing a platform
for genomic medicine in Mexico. Science. 300:295–296.
2003.PubMed/NCBI View Article : Google Scholar
|
49
|
Fricke-Galindo I, Jung-Cook H, LLerena A
and López-López M: Interethnic variability of pharmacogenetic
biomarkers in Mexican healthy volunteers: A report from the RIBEF
(Ibero-American Network of Pharmacogenetics and Pharmacogenomics).
Drug Metab Pers Ther. 31:61–81. 2016.PubMed/NCBI View Article : Google Scholar
|
50
|
Scheen AJ: Towards a genotype-based
approach for a patient-centered pharmacologic therapy of type 2
diabetes. Ann Transl Med. 3 (Suppl 1)(S36)2015.PubMed/NCBI View Article : Google Scholar
|
51
|
Chung EK, Cheatham SC, Fleming MR, Healy
DP and Kays MB: Population Pharmacokinetics and Pharmacodynamics of
Meropenem in Nonobese, Obese, and Morbidly Obese Patients. J Clin
Pharmacol. 57:356–368. 2017.PubMed/NCBI View Article : Google Scholar
|
52
|
Jusko WJ: Clarification of contraceptive
drug pharmacokinetics in obesity. Contraception. 95:10–16.
2017.PubMed/NCBI View Article : Google Scholar
|
53
|
Dostalek M, Akhlaghi F and Puzanovova M:
Effect of diabetes mellitus on pharmacokinetic and pharmacodynamic
properties of drugs. Clin Pharmacokinet. 51:481–499.
2012.PubMed/NCBI View Article : Google Scholar
|
54
|
Burge MR, Sood V, Sobhy TA, Rassam AG and
Schade DS: Sulphonylurea-induced hypoglycaemia in type 2 diabetes
mellitus: A review. Diabetes Obes Metab. 1:199–206. 1999.PubMed/NCBI View Article : Google Scholar
|
55
|
Burge MR, Schmitz-Fiorentino K, Sood V and
Schade DS: Effect of immediate-release glipizide on hypoglycemic
vulnerability in fasted, elderly patients with type 2 diabetes.
JAMA. 281:1084–1085. 1999.PubMed/NCBI
|
56
|
Jönsson A, Hallengren B, Rydberg T and
Melander A: Effects and serum levels of glibenclamide and its
active metabolites in patients with type 2 diabetes. Diabetes Obes
Metab. 3:403–409. 2001.PubMed/NCBI View Article : Google Scholar
|
57
|
Peart GF, Boutagy J and Shenfield GM: The
metabolism of glyburide in subjects of known debrisoquin phenotype.
Clin Pharmacol Ther. 45:277–284. 1989.PubMed/NCBI View Article : Google Scholar
|
58
|
Tracewell WG, Stalker DJ, Maloley PA,
Gallagher TF and Gwilt PR: Population pharmacokinetics of glyburide
in patients with well-controlled diabetes. Pharmacotherapy.
18:51–56. 1998.PubMed/NCBI View Article : Google Scholar
|
59
|
Gong L, Goswami S, Giacomini KM, Altman RB
and Klein TE: Metformin pathways: Pharmacokinetics and
pharmacodynamics. Pharmacogenet Genomics. 22:820–827.
2012.PubMed/NCBI View Article : Google Scholar
|
60
|
Spear BB, Heath-Chiozzi M and Huff J:
Clinical application of pharmacogenetics. Trends Mol Med.
7:201–204. 2001.PubMed/NCBI View Article : Google Scholar
|
61
|
Aspinall MG and Hamermesh RG: Realizing
the promise of personalized medicine. Harv Bus Rev. 85:108–117.
165:2007.PubMed/NCBI
|
62
|
García A LM, Villarreal RE, Galicia RL,
Martínez GL and Vargas DER: The cost of polypharmacy in patients
with type 2 diabetes mellitus. Rev Med Chil. 143:606–611. 2015.(In
Spanish). PubMed/NCBI View Article : Google Scholar
|
63
|
Quilliam BJ, Ozbay AB, Sill BE and Kogut
SJ: The association between adherence to oral anti-diabetic drugs
and hypoglycaemia in persons with Type 2 diabetes. Diabet Med.
30:1305–1313. 2013.PubMed/NCBI View Article : Google Scholar
|
64
|
Toledo C, Avila L, García S and Gómez H:
Therapy adherence determinants and metabolic control in Type 2
Diabetes outpatients. Rev Mex Cienc Farm. 39(9)2008.
|
65
|
Durán-Varela BR, Rivera-Chavira B and
Franco-Gallegos E: Apego al tratamiento farmacológico en pacientes
con diagnóstico de diabetes mellitus tipo 2. Salud Publica Mex.
43(7)2001.
|
66
|
Lugo-Palacios DG, Cairns J and Masetto C:
Measuring the burden of preventable diabetic hospitalisations in
the Mexican Institute of Social Security (IMSS). BMC Health Serv
Res. 16(333)2016.PubMed/NCBI View Article : Google Scholar
|
67
|
Hernández-Ávila M, Gutiérrez J and
Reynoso-Noverón N: Diabetes mellitus en México. El estado de la
epidemia. Salud Publica Mex. 55 (Suppl 2)(7)2013.PubMed/NCBI
|
68
|
Hanefeld M, Patwardhan R and Jones NP;
Rosiglitazone Clinical Trials Study Group: A one-year study
comparing the efficacy and safety of rosiglitazone and
glibenclamide in the treatment of type 2 diabetes. Nutr Metab
Cardiovasc Dis. 17:13–23. 2007.PubMed/NCBI View Article : Google Scholar
|
69
|
Jiménez-Corona A, Aguilar-Salinas CA,
Rojas-Martínez R and Hernández-Ávila M: Type 2 diabetes and
frecuency of prevention and control measures. Salud Publica Mex. 55
(Suppl 2):S137–S143. 2013.(In Spanish). PubMed/NCBI
|
70
|
Degli Esposti L, Saragoni S, Buda S and
Degli Esposti E: Clinical outcomes and health care costs combining
metformin with sitagliptin or sulphonylureas or thiazolidinediones
in uncontrolled type 2 diabetes patients. Clinicoecon Outcomes Res.
6:463–472. 2014.PubMed/NCBI View Article : Google Scholar
|